J&J CFO Says Stronger Dollar Hurt Profit Outlook

The transcript discusses a company's financial performance, highlighting strong earnings and cost management despite currency impacts. It covers the pharmaceutical sector, focusing on Remicade and biosimilar competition, and strategic growth through acquisitions. The discussion also touches on policy impacts, including healthcare access and drug pricing, in light of potential changes under a revised Obamacare.

What is the company's outlook regarding the biosimilar competition for Remicade?

What were the key topics discussed during the CEO's meeting with President Trump?